Reuters logo
3 个月前
BRIEF-Biolinerx announces regulatory submission for phase 1B trial of BL-8040
2017年5月22日 / 上午11点21分 / 3 个月前

BRIEF-Biolinerx announces regulatory submission for phase 1B trial of BL-8040

1 分钟阅读

May 22 (Reuters) - Bioline Rx Ltd

* Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML

* Trial, named battle, is expected to commence in second half of 2017, following receipt of regulatory approval Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below